Lilly taps Abbisko for $1.9B discovery deal
· tamra sami
AI Briefing
- Abbisko Therapeutics partners with Eli Lilly for $1.9B discovery deal to develop innovative medicines.
- Collaboration aims to advance novel drug candidates with global potential across multiple targets.
- Terms of the deal will support Lilly's efforts to discover and develop new medicines.
Context
Eli Lilly and Co. has entered a research collaboration and license agreement with Abbisko Therapeutics Co. Ltd. The agreement aims to discover and develop medicines across multiple targets.
The agreement has a value of $1.9B and is intended to advance novel drug candidates with global potential.
Advertisement